Physician profile
Paul Hillesheim
NPI 1942361688
$448.30
in general payments reported to CMS, 2019-2025
8 companies · $190 in 2025
The $190 reported for 2025 was more than what a typical Dermatopathology (Pathology) provider received nationally (typical 2025 total: $119).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $182 · 2023: $21.21 · 2024: $55.09 · 2025: $190.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $266.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $266.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Roche Diagnostics Corporation | $166.12 | 2022 | |
| Astrazeneca Pharmaceuticals Lp | $152.04 | 2024-2025 | Lynparza, Tagrisso |
| Merck Sharp & Dohme LLC | $33.85 | 2024 | Keytruda |
| Radiometer America, INC | $21.21 | 2023 | |
| Pharmacosmos Therapeutics INC. | $20.42 | 2025 | Monoferric |
| Geron Corporation | $19.58 | 2025 | Rytelo |
| Adc Therapeutics America, INC. | $19.13 | 2025 | |
| Qiagen, LLC | $15.95 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Hillesheim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.